MedTrace Logo

Radiotherapy in Primary Mediastinal Lymphoma

NCT01230008 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 198

Last updated 2010-10-28

No results posted yet for this study

Summary

The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP

Conditions

  • Adjuvant Radiotherapy on Complete Remission Patients

Interventions

RADIATION

no drugs

Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP

Sponsors & Collaborators

  • Instituto Mexicano del Seguro Social

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2007-06-30
Completion
2009-12-31

Countries

  • Mexico

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01230008 on ClinicalTrials.gov